Hubert Chen

Hubert C.
Chen is Chief Medical Officer at Viking Therapeutics, Inc. since 2026.
Former positions include President & Chief Scientific Officer at Forte Biosciences, Inc. from 2022 to 2024; Chief Medical Officer at Metacrine, Inc. from 2018 to 2021; Chief Medical & Scientific Officer at Pelican, Inc. from 2014 to 2018; Vice President-Clinical Development at Rein Therapeutics, Inc. from 2013 to 2014; Vice President-Translational Medicine at Regulus Therapeutics, Inc. from 2009 to 2012; Assistant Clinical Professor at The University of California, San Francisco from 2002 to 2012; Associate Director-Medical Sciences at Amgen, Inc. from 2004 to 2006; Senior Director-Clinical Research at Amylin Pharmaceuticals, Inc.; and Staff Research Investigator at The J.
David Gladstone Institutes.
Education includes a doctorate from The Trustees of Columbia University in The City of New York in 1995 and an undergraduate degree from Stanford University in 1991.